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Abstract
As part of the National HIV Behavioral Surveillance System among men who have sex with men 
(MSM) in Denver, Colorado, we assessed knowledge of pre-exposure prophylaxis (PrEP); 
willingness to use PrEP; and potential changes in risk behaviors among HIV-negative participants 
reporting sexual activity with a male partner in the preceding 12 months. We examined knowledge 
of PrEP before (2008) and after (2011) results of the iPrEx trial were available. Of the 425 
participants in the 2008 sample, 91 (21 %) were aware of PrEP compared to 131 (28 %) of the 461 
participants in the 2011 sample (adjusted prevalence ratio: 1.43, 95 % confidence interval: 1.18, 
1.72). Despite the increase in 2011, few MSM in Denver were aware of PrEP. Educating high-risk 
MSM about the potential utility of PrEP as an adjunct to other effective prevention methods is 
needed when considering the addition of PrEP to the HIV prevention arsenal.
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Pre-exposure prophylaxis (PrEP) with antiretroviral therapy has emerged as a promising 
biomedical strategy for preventing human immunodeficiency virus (HIV) infection [1–7]. 
Recently completed clinical trials evaluating the safety and efficacy of daily oral doses of 
tenofovir disoproxil fumarate (TDF), marketed as Viread, and a combination of TDF and 
emtricitabine (FTC), marketed as Truvada, in men who have sex with men (MSM) and 
heterosexually active men and women have shown the benefit of tenofovir-based PrEP for 
preventing new HIV infection [8–10]. The iPrEx trial was the first of these trials to release 
results (November 2010) and showed that once daily oral TDF–FTC provided a 44 % 
reduction in HIV incidence among MSM [10]. In July 2012, the U.S. Food and Drug 
Administration approved the TDF–FTC combination pill for PrEP [11]. The Centers for 
Disease Control and Prevention (CDC) has issued interim guidance for the safe and effective 
use of PrEP among MSM, heterosexually active adults, and persons who inject drugs [12–
14].
The effectiveness of PrEP for HIV prevention is dependent on people's awareness of PrEP, 
its uptake, and behaviors related to taking PrEP (e.g. medication adherence, change in risk 
behaviors) [15, 16]. In the United States, MSM are disproportionately affected by HIV and 
are, therefore, a priority population for PrEP. Several surveys of MSM, conducted before the 
iPrEx trial results were available, showed that knowledge and use of PrEP were limited 
among MSM [17–20]. In a sample of high-risk substance-using MSM from four major U.S. 
cities, non-prescribed PrEP use was reported by 2 % of HIV-negative respondents, and less 
than 3 % of HIV-positive respondents reported giving the drug to their sex partners [21]. 
Among 227 HIV-negative MSM surveyed in Boston, 74 % reported a willingness to use 
PrEP in the future after being educated about its potential for HIV prevention [19]. An 
equally important question is whether MSM who are willing to take PrEP might alter their 
HIV risk behaviors and engage in risk compensation (e.g., decrease condom use or increase 
number of sex partners). In a sample of 180 HIV-negative high-risk MSM in New York 
City, 35 % of those who would use PrEP reported that they would likely decrease condom 
use while using PrEP [22].
To add to the knowledge base regarding awareness of and possible future uptake of PrEP, 
we assessed knowledge of, and attitudes towards, daily oral PrEP for HIV prevention in two 
samples of urban MSM recruited through the National HIV Behavioral Surveillance System 
(NHBS) in Denver, Colorado. One sample was recruited in 2008 prior to the release of the 
iPrEx trial results and the second sample was recruited in 2011, after the iPrEx results were 
made public. Our goal was to characterize those likely to accept PrEP and to examine 
differences in PrEP knowledge and acceptance during the two time periods.
Methods
National HIV Behavioral Surveillance System (NHBS)
NHBS is a CDC-funded behavioral surveillance system conducted through annual rotating 
cycles of surveys and HIV testing targeting one of three populations at high risk for 
acquiring HIV: MSM, persons who inject drugs, and heterosexuals at increased risk for HIV 
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infection. NHBS data are used to monitor prevalence and trends in HIV-related risk and 
testing behaviors and access to HIV prevention services [23]. During the MSM cycles, local 
surveillance staff conduct venue-based, time-space sampling following the national NHBS 
protocol, which organizes sampling activities into three components. First, staff conduct 
formative research to identify the venues, times, and methods to recruit MSM. Next, staff 
construct sampling frames of eligible venues and venue-specific, daytime periods that meet 
MSM attendance, logistical, and safety eligibility criteria. A calendar of sampling events is 
constructed by randomly selecting venues and day-time periods from the sampling frame. 
CDC is in the process of developing weights to account for variations in venue attendance 
and likelihood of being selected for NHBS participation. The final component of venue-
based time-space sampling involves recruiting and interviewing men during sampling 
events.
In Denver, sampling events were conducted between August and November 2008 for the 
second NHBS cycle among MSM (NHBS-MSM2) and between August and November 2011 
for the third cycle of MSM (NHBSMSM3). During each 4-h sampling event, NHBS field 
staff approached men at selected venues to assess eligibility. Selected venues included bars, 
dance clubs, bathhouses, parks, and local grocery stores. The venues at which sampling 
events took place remained largely unchanged between the 2008 and 2011 MSM cycles. For 
both cycles, all potential participants had to be: (1) born male (2) approached by study staff 
at the sampled venues, (3) 18 years or older, (4) residents of the Denver metropolitan 
statistical area, (5) not previously completed an interview for the current NHBS-MSM cycle, 
(6) able to complete the survey in English or Spanish, and (7) able to provide informed 
consent. Neither sexual orientation nor same-sex behaviors were eligibility criteria. All 
NHBS activities were voluntary and anonymous. Verbal informed consent was obtained 
from eligible participants. Participants were also offerred HIV testing.
Pre-Exposure Prophylaxis (PrEP) Supplement
Participants completed an interviewer-administered behavioral risk survey using handheld 
computers. The behavioral risk survey included questions about sexual behaviors, substance 
use, STI history, and HIV testing. In addition to the behavioral risk survey, which is a 
standardized questionnaire used across all NHBS sites, participants completed a shorter 
local questionnaire. In Denver, a PrEP-specific supplemental questionnaire was included 
during the 2008 (NHBS-MSM2) and 2011 (NHBS-MSM3) cycles to assess knowledge of 
PrEP; willingness to use PrEP if the clinical trials showed few or no side effects; willingness 
to use PrEP if the clinical trials showed PrEP prevents HIV infection in 75 and 50 % of 
people who take it daily; and potential risk compensation, including intentions to have sex 
with more partners or use condoms less frequently if PrEP were found to be effective.
To introduce the concept of PrEP, the following statement was read to participants: 
“Scientists are currently doing studies to find new ways of preventing people from becoming 
infected with HIV. In these studies, people take a pill every day that contains the same 
medicine that is used to treat people who are infected with HIV. Scientists want to know if 
taking this medicine will prevent people exposed to HIV from becoming infected with it. 
They call this method pre-exposure prophylaxis or PrEP.” Participants were then asked if 
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they had ever heard of PrEP. This was followed by the question: “imagine that PrEP was 
available today. If studies showed that PrEP has few or no side effects, would you be willing 
to take PrEP pills every day to try to protect yourself from becoming infected with HIV?” If 
participants responded in the affirmative to this question, they were asked “If these studies 
also showed that PrEP prevents HIV infection in three-quarters or 75 % of the people who 
take it daily, would you be willing to take PrEP pills every day to try to protect yourself 
from becoming infected with HIV?” If their response was in the affirmative, they were 
asked the same question but specifying 50 % rather than 75 % effectiveness. The wording of 
the questions remained the same during both cycles.
Statistical Analysis
The current analysis was restricted to participants who reported having had oral or anal sex 
with a man in the preceding 12 months and who did not report being HIV-positive. 
Descriptive frequencies are presented for each sample. χ2 statistics were calculated to 
compare the two samples from 2008 and 2011. We also generated a multivariable model 
using a generalized linear model with log link and binomial error distribution to assess the 
primary association between knowledge of PrEP and year of data collection, controlling for 
characteristics that differed significantly between the two samples. To account for potential 
correlation of observations within venues, a robust variance estimator was calculated [24]. 
Unadjusted and adjusted prevalence ratios (PR) and associated 95 % confidence intervals 
(CI) are presented. As a final step, comparisons between participants who reported 
knowledge of PrEP and those who did not were made using Chi square (χ2) statistics 
separately for each sample. Fisher's exact test was calculated when minimum expected 
frequency requirements were not met. All analyses were conducted using Stata Version 12.0 
(StataCorp, College Station, TX).
Results
2008 NHBS-MSM2 Results
Between August and November 2008, 735 men were screened for the NHBS-MSM2 survey 
in Denver, Colorado. Of these men, 503 were eligible for NHBS and completed the PrEP 
supplemental questionnaire. After excluding men who did not have sex with a man in the 
previous 12 months and those who reported being HIV positive, the resulting sample size 
was 425. Of the 425 participants included in the analysis, almost two-thirds (63 %) 
described their race/ethnicity as non-Hispanic white, 3 % identified as non-Hispanic black, 
26 % as Hispanic, and the remaining 7 % described themselves as Asian, Pacific Islander, 
American Indian/Alaskan Native or other race/ethnicity (Table 1, NHBS-MSM2). Almost 
two-thirds (66 %) of participants were over the age of 30 years, 73 % had more than a high 
school education, and 52 % reported an annual income of $40,000 or more. A little less than 
one-fourth (22 %) of participants reported living with a man they considered to be a 
boyfriend, spouse, significant other, or life partner. More than three-quarters of participants 
(77 %) reported two or more male sexual partners during the past 12 months and 37 % 
reported at least one act of unprotected anal intercourse during the past 12 months.
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A total of 91 (21 %) participants reported that they had ever heard of PrEP before their 
interview (Table 2, NHBSMSM2). Two-thirds of participants (66 %) reported that they 
would take PrEP every day if studies showed no side effects. The proportion of men in 
Denver reporting their willingness to take PrEP daily if shown to be 75 and 50 % effective 
was 60 and 45 %, respectively. Prior to the release of the iPrEX trial results, the majority of 
participants did not anticipate changing either their condom use (85 %) or the number of sex 
partners (92 %) if they were taking PrEP every day.
2011 NHBS-MSM3 Results
Between August and November 2011, 678 men were screened for NHBS-MSM3. Of these 
men, 527 were eligible for NHBS and completed the PrEP supplemental questionnaire. 
After excluding men who did not have sex with a man in the previous 12 months and those 
who reported being HIV positive, the resulting sample size was 461. Slightly more than half 
(54 %) of the 461 participants described their race/ethnicity as non-Hispanic white, 11 % 
identified as non-Hispanic black, 27 % as Hispanic, and the remaining 8 % described 
themselves as Asian, Pacific Islander, American Indian/Alaskan Native or other race/
ethnicity (Table 1, NHBS-MSM3). Almost two-thirds (62 %) of participants were over the 
age of 30 years, 76 % had more than a high school education, and 43 % reported an annual 
income of $40,000 or more. In the 2011 sample, one-fifth (20 %) of participants reported 
living with a man they considered to be a boyfriend, spouse, significant other, or life partner. 
A large majority (80 %) of participants reported two or more male sexual partners during the 
past 12 months and 36 % reported at least one act of unprotected anal intercourse during the 
past 12 months.
In the 2011 sample, a total of 131 (28 %) participants reported that they had heard of PrEP 
before their interview (Table 2, NHBS-MSM3). Compared to 66 % of the sample in 2008, 
62 % of participants in the 2011 sample reported that they would take PrEP every day if 
studies showed no side effects. In 2011, the proportions of men reporting their willingness to 
take PrEP at different levels of effectiveness was also slightly lower with 56 % of men 
reporting willingness to take PrEP every day if shown to be 75 % effective and 44 % willing 
to take daily PrEP if shown to be 50 % effective. Post iPrEx trial results being released, a 
slightly higher proportion of men in the 2011 sample reported some anticipated changes in 
behavior with 11 % reporting less frequent condom use and 10 % reporting more condom 
use. Similarly, a higher proportion of the 2011 sample reported a change in anticipated 
number of partners with 8 % anticipating fewer partners and 6 % anticipating more partners. 
This increase is compared to the 2008 sample where 3 % anticipated having fewer partners 
and 4 % anticipated having more partners (χ2 = 12.59, P = 0.002).
Multivariable Modeling Results
Among participants in the 2011 sample, 131 (28 %) had heard of PrEP compared with 91 
(21 %) participants in the 2008 sample (crude PR: 1.32, 95 % CI: 1.07, 1.65; Table 3). 
Accounting for potential clustering within each venue and the potentially confounding 
effects of race/ethnicity, age, income, anticipated changes in condom use and number of 
partners as these factors differed between the two samples, participants in the 2011 sample 
were 43 % more likely to have heard of PrEP (adjusted PR: 1.43, 95 % CI: 1.18, 1.72).
Al-Tayyib et al. Page 5













Within Sample Comparison Results
In both samples, knowledge of PrEP differed significantly by income level (Table 4). In the 
2008 sample, among participants who had heard of PrEP 65 % reported an annual income of 
$40,000 or more, 24 % reported an annual income between $20,000 and $39,000, and 11 % 
reported an annual income of $19,999 or less (χ2 = 9.23, P = 0.01). In the 2011 sample, 
among participants who had heard of PrEP 55 % reported an annual income of $40,000 or 
more, 21 % reported an annual income between $20,000 and $39,000, and 24 % reported an 
annual income less of $19,999 or less (χ2 = 10.66, P = 0.005).
Discussion
PrEP's potential impact on averting new HIV infections will depend on several factors 
including knowledge of, access to, and adherence to daily medication. We measured 
knowledge of, attitudes towards, and intentions to use daily oral PrEP for HIV prevention 
under hypothetical conditions of efficacy in two samples of MSM in Denver, Colorado 
before and after the iPrEx trial results were released. Similar to other surveys of MSM 
conducted before iPrEx trial results became available, we found limited knowledge of PrEP 
among NHBS-MSM participants in 2008, with higher levels of knowledge among NHBS-
MSM participants in 2011 [17–20]. Our results are also similar to more recent surveys of 
MSM regarding PrEP awareness after the release of the iPrEx trial results that continue to 
show limited awareness of PrEP among those most likely to benefit from its uptake [25–27].
Our findings show that, even under hypothetical conditions of few or no side effects and 
high effectiveness, nearly half of participants would be opposed to taking PrEP on a daily 
basis. Willingness to consider using PrEP varied by level of protection provided, with less 
than half of MSM in both the 2008 and 2011 samples willing to use PrEP if it was only 
shown to prevent HIV infection in 50 % of those who took it daily. This level is only 
slightly higher than the average efficacy found in the iPrEx trial. Higher proportions of 
MSM in both the 2008 and 2011 Denver samples reported being willing to use PrEP daily if 
it was shown to prevent HIV infection in 75 % of those who took it daily. The iPrEx trial 
demonstrates that efficacy greater than 90 % would be possible if PrEP is taken as 
prescribed [10].
Though our study was not specifically designed to measure gains in knowledge of PrEP as a 
result of the release of the iPrEx results and publicity, our findings confirm that knowledge 
of PrEP remains low among those most likely to benefit from its preventative potential, high 
risk MSM. Furthermore, our findings provide a longitudinal perspective on the change in 
awareness of PrEP among a convenience sample of MSM and underscore the fact that 
knowledge of PrEP did not dramatically increase with the release of findings from the 
definitive PrEP trials. Studies describing potential uptake of PrEP in an era where PrEP is no 
longer a hypothetical prevention tool are just beginning to amass [28–30]. Gaining a better 
understanding of reasons why those likely to benefit from PrEP might be reluctant to take 
daily PrEP will be integral to understanding how to maximize PrEP's contribution to HIV 
prevention outside of clinical trials. In addition, similar to other recent studies [26], our data 
suggest that community-level education must be at the heart of any plan to implement or 
expand the utilization of PrEP in MSM.
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Against the backdrop of CDC's new High-Impact Prevention approach which prioritizes the 
interventions with the greatest potential to prevent the most new infections and directs 
efforts to the populations most affected by HIV, it is imperative to continue to monitor 
attitudes towards new interventions such as PrEP in key populations like MSM. NHBS is a 
robust national system critical in monitoring trends in HIV risk behavior and can also be 
leveraged to identify emerging trends by incorporating relevant questions into the local 
questionnaire. The ability to gather data that are relevant to the local HIV epidemic in a 
timely and efficient manner across the 20 participating NHBS sites enhances the value of the 
national system. To continue to monitor knowledge of and attitudes towards PrEP, we plan 
to include the same questions (with some minor adjustments to the question wording) during 
NHBSMSM4 which is scheduled to occur in 2014.
Our study is not without limitations. First, because the survey was administered by an 
interviewer, some participants might not have accurately reported their knowledge or 
behaviors. Furthermore, asking people to respond to hypothetical scenarios and predict 
future behaviors or reasons for future behaviors is cognitively difficult and may not correlate 
well with what happens in practice. However, given that PrEP has demonstrated efficacy to 
reduce the risk of HIV infection among MSM, our study may provide some insight into how 
MSM might behave if PrEP becomes more widely available and thus could serve as an aid 
to providers or prevention practitioners when developing counseling messages. Second, our 
study was limited to respondents in one city and cannot be generalized to represent the 
views of all MSM in the United States. Third, given the design of NHBS which does not 
preclude participation in multiple cycles of NHBS there was no assessment of repeated 
participation in 2008 and 2011, making it impossible to adjust for repeated observations. 
Finally, the data included in this report are not weighted to account for variations in venue 
attendance or likelihood of being selected to participate in the survey. This may lead to an 
inaccurate measurement of some behaviors due to the fact that responses of men who 
attended venues more frequently would be over-represented while those who do not attend 
frequently would be under-represented.
If PrEP is made available to, and its use adopted by, MSM at high risk of acquiring HIV, 
and if it is provided along with routine HIV and STI screening as well as behavioral risk-
reduction and medication adherence, PrEP could contribute substantially to reducing new 
HIV infections. Interim guidance for health care providers in the United States recommends 
that PrEP only be considered for MSM at high risk of HIV infection [12]. However, given 
the groundbreaking results of the HPTN 052 trial [31], it is likely that “test and treat” 
strategies will focus on providing antiretrovirals to infected individuals to reduce HIV 
transmission rather than focusing on providing antiretrovirals to uninfected individuals to 
prevent HIV acquisition. Still, PrEP is an important addition to the HIV prevention 
armamentarium.
At the time of the survey in 2011, only 28 % of MSM in our study were aware of PrEP. 
Much work remains to be done to educate high-risk MSM about the potential utility of PrEP 
as an adjunct to other effective prevention methods. Given that a key component of PrEP's 
effectiveness is awareness of PrEP, it is imperative to develop educational messages 
targeting those most likely to benefit from PrEP and empowering them to initiate the 
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conversation with their provider. As with any comprehensive prevention plan, an 
educational component targeting the populations most at risk must be included when 
considering the addition of PrEP to the HIV prevention arsenal. Now that the efficacy and 
safety of PrEP for MSM have been demonstrated, and the importance of adherence to 
medication defined, additional surveys of MSM need to be conducted to determine levels of 
interest in using PrEP, preferred sources of PrEP delivery, and barriers to access.
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Table 1
Demographic and behavioral characteristics of two samples of men who have sex with men, National HIV 
Behavioral Surveil-lance System, Denver, Colorado, 2008 and 2011
NHBS- MSM2 (n = 425) n (%) NHBS- MSM3 (n = 461) n (%) χ2(P value)
Race/ethnicity 21.31 (<0.001)
    White, non-Hispanic 267 (63) 250 (54)
    Black, non-Hispanic 14 (3) 51 (11)
    Hispanic 112 (26) 122 (27)
    Other 32 (7) 38 (8)
Age (years) 8.27 (0.041)
    18-20 19 (4) 10(2)
    21-29 124 (29) 166 (36)
    30-39 115 (27) 127 (28)
    40+ 167 (39) 158 (34)
Education 1.13 (0.567)
    Less than high school 19 (4) 15 (3)
    High school 95 (22) 98 (21)
    More than high school 311 (73) 348 (76)
Annual income 8.69 (0.013)
    $0-$19,999 89 (21) 129 (28)
    $20,000-$39,999 113 (27) 133 (29)
    $40,000 or more 222 (52) 199 (43)
Currently live with a boyfriend/significant other 0.73 (0.393)
    Yes 94 (22) 91 (20)
    No 331 (78) 369 (80)
Number of sex partners in past 12 months 3.17 (0.205)
    1 partner 100 (23) 93 (20)
    2 or 3 partners 131 (31) 130 (28)
    4 or more partners 194 (46) 237 (52)
Unprotected anal sex in past 12 months 0.09 (0.765)
    Yes 159 (37) 168 (36)
    No 266 (63) 293 (64)
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Table 2
Knowledge of and attitudes towards pre-exposure prophylaxis (PrEP) and anticipated behavior change in two 
samples of men who have sex with men, National HIV Behavioral Surveillance System, Denver, Colorado, 
2008 and 2011
NHBS-MSM2 (n =425) n 
(%)
NHBS-MSM3 (n =461) n 
(%)
χ2(P value)
Ever heard of PrEP? 5.78 (0.016)
Yes 91 (21) 131 (28)
No 334 (79) 330 (72)
Willing to take daily PrEP, if shown to have few or no side effects? 1.47 (0.225)
Yes 280 (66) 286 (62)
No 141 (33) 171 (37)
Willing to take daily PrEP, if shown to prevent new HIV in 75 %? 0.97 (0.325)
Yes 253 (60) 260 (56)
No 171 (40) 201 (44)
Willing to take daily PrEP, if shown to prevent new HIV in 50 %? 0.33 (0.566)
Yes 193 (45) 201 (44)
No 231 (55) 260 (56)
Anticipated condom use if taking daily PrEP 5.16 (0.076)
Less frequently 43 (10) 52 (11)
More frequently 26 (6) 47 (10)
About as frequently as before 350 (82) 361 (78)
Anticipated number of sex partners if taking daily PrEP 12.59 (0.002)
Fewer partners 14 (3) 38 (8)
More partners 17(4) 29 (6)
Same number of partners 390 (92) 392 (85)
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Table 3
Association between knowledge of pre-exposure prophylaxis (PrEP) and year of data collection among men 
who have sex with men, National HIV Behavioral Surveillance System, Denver, Colorado, 2008 and 2011
Heard of PrEP Crude prevalence ratio (95 % CI) Adjusted prevalence ratio (95 % CI)*
Year of data collection
    2011 (post-iPrEx results) 131 (28) 1.33 (1.07, 1.65) 1.43 (1.18, 1.72)
    2008 (pre-iPrEx results) 91 (21) 1.0 (ref) 1.0 (ref)
*
Adjusted for race, age, income, anticipated change in condom use, and anticipated change in number of partners
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Table 4
Within sample comparisons of awareness of pre-exposure prophylaxis (PrEP) among men who have sex with 
men, National HIV Behavioral Surveillance System, Denver, Colorado, 2008 and 2011
NHBS-MSM2 in 2008 NHBS-MSM3 in 2011
Heard of PrEP 
(n = 91) n (%)
Not heard of 
PrEP (n = 334)
χ2(P value) Heard of PrEP 
(n = 131) n(%)
Not heard of 




    White, non-Hispanic 65 (71) 202 (60) 5.86 83 (63) 167 (51) 6.63
    Black, non-Hispanic 4(4) 10 (3) (0.118) 10 (7) 41 (12) (0.085)
    Hispanic 19 (21) 93 (28) 28 (21) 94 (28)
    Other - 29 (9) 10 (7) 28 (8)
Age (years)
    18–20 - 19 (6) 6.19 - 10 (3) 4.15
    21–29 27 (30) 97 (29) (0.102) 47 (36) 119 (36) (0.246)
    30–39 29 (32) 86 (26) 38 (29) 89 (27)
    40+ 35 (38) 132 (39) 46 (35) 112 (34)
Income
    $0–$19,999 10(11) 79 (24) 9.23 31 (24) 98 (30) 10.66
    $20,000–$39,999 22 (24) 91 (27) (0.01) 28 (21) 105 (32) (0.005)
    $40,000 or more 59 (65) 163 (49) 72 (55) 127 (38)
Anticipated condom use if taking daily PrEP
    Less frequently 6 (7) 37 (11) 7.07 16 (12) 36 (11) 3.40
    More frequently - 25 (7) (0.029) 8 (6) 39 (12) (0.182)
    About as frequently as befoi e 82 (92) 268 (81) 107 (82) 254 (77)
Anticipated number of sex partners if taking daily PrEP
    Fewer partners - 14(4) 3.91 5 (4) 33 (10) 8.57
    More partners 4 (4) 13 (4) (0.141) 4 (3) 25 (8) (0.014)
    Same number of partners 85 (96) 305 (92) 121 (93) 271 (82)
Column numbers may not sum to total due to missing data, small cell size numbers suppressed
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